<DOC>
	<DOCNO>NCT00447070</DOCNO>
	<brief_summary>It known certain antiviral therapy , socalled protease inhibitor , use treatment HIV infection untowarded effect blood vessel , promote early occurence atherosclerosis . A new protease inhibitor , atazanavir , show negative effect level blood cholesterol hypothesize may indicate atazanavir less prone induce atherosclerosis . An early sign atherosclerosis reduce vasomotion study investigate influence atazanavir functionality conduit blood vessel compare `` standard '' antiviral therapy .</brief_summary>
	<brief_title>Effect Atazanavir Endothelial Function HIV-Infected Patients</brief_title>
	<detailed_description>Indication : Dyslipidemia Type II HIV-Infected Patients Primary Objectives : Change flow-mediated dilation forearm 6 month use protease inhibitor atazanavir potent antiviral therapy combination compare combination include current proteinase inhibitor . Secondary Objectives : Changes plasma lipid profile clinical chemistry parameter 6 month treatment compare baseline . Study Design : This multicenter , observer-blind ( measurement vessel parameter statistical evaluation ) , treatment-controlled , randomize , study 2 treatment group . Planned Total Sample Size : ( 40-50 ) eligible randomize patient ( 20-25 per group ) 2-5 center . Subject Selection Criteria : - Men woman , 18 65 year old . - HIV-infection , document HIV-antibody ELISA either positive immunoblot HIV-antibodies presence HIV1 blood . - Two consecutive Roche Ultrasensitive Amplicor test show plasma HIV-1 RNA &lt; 50 copies/ml within 60 day prior study entry . - CD4 count &gt; 100 cells/ml 60 day prior study entry . - Stable antiretroviral therapy least 12 week prior study entry ( protease inhibitor plus 2 NRTIs ) . - Patient 's treatment history allow , opinion investigator , atazanavir replacement current PI , i.e . continued viral suppression expect base upon patient 's treatment history result previous resistance testing , available . - Fasting LDL-cholesterol &gt; 3.0 mmol/l . Contraindications participation : - Known coronary artery disease , hypertension , peripheral artery disease , cerebrovascular disease . - Diabetes mellitus . - Serious illness require systemic treatment and/or hospitalization within 14 day prior study entry . - Any contraindication study medication . - Currently non-nucleoside reverse transcriptase inhibitor ( NNRTI ) ( previous exposure allow ) . - Previous virologic failure proteinase inhibitor-containing regimen consequence poor adherence therapy drug adverse event ; i.e . virologic failure probably due lack potency drug regimen , may consecutively result protease resistance mutation . - Previously document protease resistance mutation know result cross-resistance atazanavir . - Any lipid lowering drug within 4 week prior study entry . - Testosterone anabolic steroid unless stable therapy least 12 week prior study entry . - Systemic glucocorticoid , long-acting inhaled steroid immunomodulators within 30 day prior study entry ( prednisone &lt; 10mg/day equivalent permit . - Drug alcohol abuse , opinion investigator render patient unreliable participation . - Participation drug/treatment study . Test Drugs : 1 . Atazanavir capsule daily standard dose ( 2 x 200 mg daily ) 2 . Continuation current protease inhibitor</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Men woman , 18 65 year old . HIVinfection , document HIVantibody ELISA either positive immunoblot HIVantibodies presence HIV1 blood . Two consecutive Roche Ultrasensitive Amplicor test show plasma HIV1 RNA &lt; 50 copies/ml within 60 day prior study entry . CD4 count &gt; 100 cells/ml 60 day prior study entry . Stable antiretroviral therapy least 12 week prior study entry ( protease inhibitor plus 2 NRTIs ) . Patient 's treatment history allow , opinion investigator , atazanavir replacement current PI , i.e . continued viral suppression expect base upon patient 's treatment history result previous resistance testing , available . Fasting LDLcholesterol &gt; 3.0 mmol/l . Known coronary artery disease , hypertension , peripheral artery disease , cerebrovascular disease . Diabetes mellitus . Serious illness require systemic treatment and/or hospitalization within 14 day prior study entry . Any contraindication study medication . Currently nonnucleoside reverse transcriptase inhibitor ( NNRTI ) ( previous exposure allow ) . Previous virologic failure proteinase inhibitorcontaining regimen consequence poor adherence therapy drug adverse event ; i.e . virologic failure probably due lack potency drug regimen , may consecutively result protease resistance mutation . Previously document protease resistance mutation know result crossresistance atazanavir . Any lipid lowering drug within 4 week prior study entry . Testosterone anabolic steroid unless stable therapy least 12 week prior study entry . Systemic glucocorticoid , longacting inhaled steroid immunomodulators within 30 day prior study entry ( prednisone &lt; 10mg/day equivalent permit . Drug alcohol abuse , opinion investigator render patient unreliable participation . Participation drug/treatment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>HIV-infection</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Endothelial Dysfunction</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>treatment experience</keyword>
</DOC>